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Edited by Veli-Pekka LehtoAbstract The purpose of the present study is to identify bioac-
tive compounds with potential for X-linked adrenoleukodystro-
phy (X-ALD) pharmacological therapy. Various plant natural
products including ﬂavonoids were tested for their ability to ame-
liorate the abnormality of very long chain fatty acid (VLCFA)
metabolism in cultured skin-ﬁbroblasts from X-ALD patients.
Of the compounds tested, baicalein 5,6,7-trimethyl ether (baica-
lein-tri-Me) was found to signiﬁcantly stimulate the VLCFA
b-oxidation activity. Furthermore, the incorporation of
[1-14C]lignoceric acid into cholesteryl esters was markedly re-
duced towards the normal level and the VLCFA (C24:0 and
C26:0) content was decreased. These results make baicalein-
tri-Me a candidate for the therapeutic compound for X-ALD.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Baicalein1. Introduction
X-linked adrenoleukodystrophy (X-ALD) is an inherited
disorder characterized by progressive demyelination of the
central nervous system and adrenal insuﬃciency. The bio-
chemical characterization of the disease is made based on
the accumulation of pathognomonic amounts of saturated
very long chain fatty acids (VLCFA, >C22) in body ﬂuids
and tissues, including brain white matter and adrenal glands,Abbreviations: ABC protein, ATP-binding cassette protein; ALDP,
adrenoleukodystrophy protein; ALDRP, ALDP-related protein; bai-
calein-tri-Me, baicalein 5,6,7-trimethyl ether; LCFA, long chain fatty
acid; X-ALD, X-linked adrenoleukodystrophy; PMP70, 70-kDa per-
oxisomal membrane protein; VLCFA, very long chain fatty acid
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doi:10.1016/j.febslet.2004.11.102and also in skin ﬁbroblasts of the patients [1–3]. It is the
most common peroxisomal disorder, aﬀecting approximately
1 in 15000–30000 males [4], and is due to a dysfunction of
adrenoleukodystrophy protein (ALDP/ABCD1), which be-
longs to the ATP-binding cassette (ABC) protein family.
In skin ﬁbroblasts retrieved from X-ALD patients (X-ALD
ﬁbroblasts), VLCFA b-oxidation activity is decreased and
VLCFAs (C24:0 and C26:0) accumulated [5]. The precise
mechanisms of ALDP in VLCFA metabolism are still un-
clear. In previous studies, we suggested that 70-kDa peroxi-
somal membrane protein (PMP70/ABCD3), another
peroxisomal ABC protein, might be involved in the import
of LCFA-CoA into peroxisomes [6], and ALDP as well as
PMP70 can bind and hydrolyze ATP [7,8]. We therefore
speculate that ALDP could be involved in ATP-dependent
transport of fatty acids or certain other molecules which
are involved in fatty acid metabolism.
During the past decades, many attempts have been made to
cure X-ALD, but none of the methods put forward to date has
inﬂuenced the neurodegenerative progression of the lethal dis-
ease. A diet approach using a glyceroltrioleate/glyceroltrieru-
cate mixture, known as Lorenzos oil, combined with a
VLCFA-poor diet, is now generally attempted [9]. However,
the results of this therapy in X-ALD patients already present-
ing with symptoms have been disappointing. At present, bone
marrow transplantation is an accepted procedure in X-ALD
patients in the early stages of neurologic symptoms so as to
provide long-term stabilization, but the procedure carries a
high risk [10]. Therefore, new pharmacological therapies are
obviously needed in order to obtain a better prognosis for
X-ALD patient.
Flavonoids, plant polyphenolic compounds, have been
known to have a number of biological activities including
anti-hyperlipidemia, anti-inﬂammatory, anti-oxidant and
anti-apoptotic eﬀects [11]. These ﬁndings indicate that certain
ﬂavonoids have attracted attention as possible chemotherapeu-
tic agents. We have found for the ﬁrst time that the baicalein
5,6,7-trimethyl ether (baicalein-tri-Me) can normalize VLCFA
b-oxidation and VLCFA-cholesterol esteriﬁcation in X-ALDublished by Elsevier B.V. All rights reserved.
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ﬁbroblasts tends to be improved by this ﬂavonoid.Fig. 1. The eﬀect of various ﬂavonoids on VLCFA b-oxidation in X-
ALD ﬁbroblasts. X-ALD ﬁbroblasts (R518Q) were incubated in the
absence or presence of 20 lM of various ﬂavonoids for 72 h. Media2. Materials and methods
2.1. Flavonoids
Flavonoids were prepared from plants as described [12]. The ﬂavo-
noids tested were ginkgetin, linarin, cosmosiin, scutellarein, hyperin,
quercitrin, rutin, luteolin 7-glucoside, isoquercitrin, luteolin, diosme-
tin, apigenin, kaempferol, quercetin, myricetin, myricitrin, eriodictyol,
hesperidin, miscanthoside, distylin, astilbin, fustin, formononetin,
sophoricoside, genistein, orientin, vitexin, embinin, amentoﬂavone,
swertisin, liquiritin, fukugetin, wogonin, prunin, neoponcirin, baicalin,
baicalein, baicalein-tri-Me, pectolinarigenin, nelumboside, quercimeri-
trin, scoparin, narcissin, aricularin, reynoutrin, luteolin tetraacetate,
chrysoeriol, fortunellin, diosmetin 7-arabinoside, diosmetin 7-gluco-
side, pedalitin, eupatoin, cirsiliol, phellamurin, axifolin, kaempferol
3-arabinoside, kaempferol 3-galactoside, kaempferol 7-glucoside, aca-
ciin, cinaiin, rhoifolin, kaempferitrin, kaempferol 3-rhamnosyl(1–
3)glucoside, circimaritin, pectolinarin, sorbarin, isorhamnetin, and
quercetin 5,7,3 0,4 0-tetramethyl ether. In some experiments, baicalin,
baicalein and baicalein-tri-Me were purchased from Extrasynthese S.
A. (Genay, France).
2.2. Cell culture
Human skin ﬁbroblasts (normal) and X-ALD ﬁbroblasts (R518Q
[13] and #163 [14]) were cultured in DMEM (ICN, Aurora, OH), con-
taining 10% fetal bovine serum and maintained in a humidiﬁed atmo-
sphere with 95% air and 5% CO2 at 37 C.
2.3. b-Oxidation of fatty acids
b-Oxidation assay was performed essentially as described previously
[15,16]. Fatty acid oxidation reaction was initiated by adding 4 nmol of
[1-14C]palmitic acid (60 mCi/mmol) or [1-14C]lignoceric acid (53 mCi/
mmol) to the ﬁbroblasts cultured in DMEM without fetal calf serum.
The fatty acids were dissolved in 10 mM a-cyclodextrin by sonication.
The acid-soluble radioactivity in the medium was measured by a scin-
tillation counter. The radioactive fatty acids were purchased from
Moravek Biochemicals (California, USA).
2.4. Analysis of fatty acid contents by gas–liquid chromatography
Total lipids were extracted from ﬁbroblasts according to the method
of Bligh and Dyer [17]. Fatty acids in the total lipid extracts were con-
verted into fatty acid methylesters by boiling in methanol containing
5% (w/v) hydrogen chloride (Tokyo Kasei, Tokyo) for 3 h, which
methylesters were puriﬁed by silica gel thin-layer chromatography
using a mixture of petroleum ether/diethyl ether/acetic acid (80:30:1,
v/v/v) as a developing solvent. The fatty acid methylesters were ana-
lyzed by gas–liquid chromatography with a capillary column (DB-
225MS, J&W Scientiﬁcs, Folsom, CA). Identiﬁcation of the fatty acid
methyl esters on gas–liquid chromatography was carried out by using
authentic standards (Sigma, St. Louis, MO).
2.5. Incorporation of labeled lignoceric acid into cholesterol esters and
triacylglycerol
Cells were incubated with serum-free medium containing 4 nmol
[1-14C]lignoceric acid for 6 h. Unincorporated fatty acids were re-
moved by washing with PBS containing 0.1 mg/ml lipid-free bovine
serum albumin. The total cellular lipids were extracted, re-dissolved
in CHCl3/MeOH (2:1, v/v), and separated by TLC using the solvent
system of diethyl ether/petroleum ether/formic acid (15:85:1, v/v/v).
Cholesteryl oleate, triolein, cholesterol, oleate and phosphatidyl cho-
line were co-developed as standards and detected by iodine vapor.
The radioactivity in each lipid fraction was quantiﬁed with a BAS
5000 (Fuji Film, Japan).were replaced every 24 h with the addition of fresh reagents. VLCFA
b-oxidation assay was carried out using [1-14C]lignoceric acid as
substrate after the 72-h incubation. Lovastatin (5 lM), known to
activate VLCFA b-oxidation, was also tested. Data are means ± S.D.
of three diﬀerent experiments. Diﬀerences between the treated and
non-treated groups were considered signiﬁcant when P < 0.05, accord-
ing to Students t test. (\, P < 0.05 vs. X-ALD).2.6. Other methods
Immunoblotting was performed as described previously [18] using
ECL+Plus Western blotting detection reagent (Amersham Biosci-
ences, Piscataway, NJ). Rabbit anti-ALDP and PMP70 antibodies
were prepared as described previously [19,20]. Rabbit anti-ALDRPantibody was raised against the C-terminal 14 amino acids
(CDSVLKTIKNEDETS) for human ALDRP. Protein concentration
was determined by the method of Bradford using immunogloublin as
the standard [21]. P values were calculated using the two-tailed Stu-
dents t test. A P value of <0.05 was used as the criterion for statis-
tical signiﬁcance.3. Results
3.1. Eﬀect of various ﬂavonoids on VLCFA b-oxidation in
X-ALD ﬁbroblasts
The VLCFA b-oxidation activity in X-ALD ﬁbroblasts
(R518Q) was decreased by 70% as compared with normal
ﬁbroblasts (as shown in Fig. 1). We ﬁrst administered vari-
ous ﬂavonoids (68 samples) and terpenoids (12 samples), to
X-ALD ﬁbroblasts and analyzed the VLCFA (C24:0) b-oxi-
dation activity to search for bioactive compounds that stim-
ulate the activity. Among them, 17 ﬂavonoids showed some
stimulation activities in a primary screening. We therefore
re-analyzed the 17 ﬂavonoids with lovastatin (Fig. 1). The
results show that diosmetin, quercetin, genistein, baicalein-
tri-Me, diosmetin 7-glucoside, isorhamnetin and quercetin
5,7,3 0,4 0-methyl ether signiﬁcantly accelerated the VLCFA
b-oxidation (P < 0.05). The stimulation appeared to be high-
er than that by lovastatin, which is reported to activate
VLCFA b-oxidation in X-ALD ﬁbroblasts [22]. Of the com-
pounds tested, baicalein-tri-Me showed the highest activities
with less than 5% cell death. The stimulation activity was
dose-dependent up to 30 lM (Fig. 2A) and reached a max-
imum at two days of treatment (Fig. 2B). A further investi-
gation was then made of the eﬀect of baicalein-tri-Me on
various types of lipid metabolism.
Table 1
Eﬀect of baicalein-tri-Me on VLCFA b-oxidation in diﬀerent X-ALD
mutant ﬁbroblasts
Palmitic acid
(C16:0) (pmol/h/
mg protein)
Lignoceric acid
(C24:0) (pmol/h/
mg protein)
Healthy control
None (DMSO) 225.7 ± 3.5 171.3 ± 7.4
Baicalein-tri-Me 357.3 ± 27.2 373.2 ± 1.3
X-ALD (R518Q)
None (DMSO) 369.0 ± 90.2 71.1 ± 4.5
Baicalein-tri-Me 488.5 ± 42.2 154.1 ± 17.7
X-ALD (#163)
None (DMSO) 296.9 ± 19.0 74.4 ± 1.4
Baicalein-tri-Me 589.9 ± 98.6 133.2 ± 9.5
Healthy control and X-ALD ﬁbroblasts, R518Q and #163, were
incubated with 30 lM of baicalein-tri-Me for three days. LCFA and
VLCFA b-oxidation activities were analyzed using [1-14C]palmitic acid
and [1-14C]lignoceric acid as substrate, respectively. Data are
means ± S.D. of three diﬀerent experiments.
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Fig. 2. The dose- and time-dependent eﬀect of baicalein-tri-Me on
VLCFA b-oxidation. X-ALD ﬁbroblasts (R518Q) were treated with
various concentrations of baicalein-tri-Me for three days (A) or
cultured in the presence of baicalein-tri-Me at a concentration of 30
lM (B). The enzyme assay for b-oxidation was carried out as in Fig. 1.
Data are shown as percentage of the activity in normal ﬁbroblasts
(250.5 ± 20.7 pmol/h/mg protein).
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activity
Fig. 3 shows the chemical formulas of the baicalein-tri-Me
and baicalen derivatives. Baicalein-tri-Me has a chemical
structure of which the hydroxyl groups at 5, 6 and 7 of baica-
lein are substituted by methoxyl groups. In contrast, baicalin is
a baicalein derivative conjugated with glucuronic acid at the
hydroxyl residue of position 7. Interestingly, baicalin and
baicalein decreased rather than the VLCFA b-oxidation activ-
ity as compared with untreated control, to 49% and 83%,
respectively.
3.3. Baicalein-tri-Me stimulates LCFA as well as VLCFA
b-oxidation
To avoid the possibility that the aﬀect was restricted to cer-
tain X-ALD missense mutants, we attempted to elucidate the
eﬀect of the ﬂavonoid on the activity in diﬀerent mutant X-Baicalin
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Fig. 3. Chemical formulas of the baicalein derivatives and their eﬀects
on VLCFA b-oxidation. X-ALD ﬁbroblasts were cultivated in the
presence of baicalin, baicalein and baicalein-tri-Me (ﬁnal conc. 30 lM)
for three days. b-Oxidation activities were expressed as percentage of
control (82.7 ± 11.1 pmol/h/mg protein).ALD ﬁbroblasts; #163 (lacking ALD mRNA and protein,
and immortalized by transformation with SV40) and R518Q
(harboring the missense mutation of 1939G to A correspond-
ing to the arginine at the 518 amino acid residue). Baicalein-
tri-Me stimulated VLCFA b-oxidation in both of the mutant
X-ALD ﬁbroblasts; #163 by 79% and R518Q by 117% (Table
1), suggesting that the eﬀect was not restricted to a certain mis-
sense mutant. In addition, the ﬂavonoid stimulated not only
VLCFA but also LCFA b-oxidation activity in X-ALD ﬁbro-
blasts. The eﬀect was also observed in healthy control ﬁbro-
blasts (Table 1). VLCFA b-oxidation is attributed to
peroxisomes because the activity is not found in peroxisome-
deﬁcient ﬁbroblasts (such as Zellweger ﬁbroblasts). We ana-
lyzed the eﬀects of antimycin A, an inhibitor of mitochondrial
complex III, on b-oxidation. The inhibitor reduced the LCFA
b-oxidation activity by 70% and also VLCFA b-oxidation by
49%, which is consistent with the results reported by McGuin-
ness et al. [23]. In the presence of antimycin A, the baicalein-
tri-Me-mediated stimulation of the VLCFA b-oxidation was
not observed (data not shown).
3.4. Eﬀect of baicalein-tri-Me on fatty acid contents in X-ALD
ﬁbroblasts
Since baicalein-tri-Me stimulated the VLCFA b-oxidation
activity, we next evaluated whether this ﬂavonoid has an abil-
ity to decrease the VLCFA (>C22) content in X-ALD ﬁbro-
blasts. The percentage of cerotic acid (C26:0) content in
X-ALD ﬁbroblasts was about 11 times higher than that in nor-
mal ﬁbroblasts (Fig. 4). In contrast, C20:0, C22:0 and C24:0
contents in X-ALD ﬁbroblasts were not much diﬀerent from
those in normal ﬁbroblasts. By treatment with baicalein-
tri-Me, behenic acid (C22:0) and lignoceric acid (C24:0) were
signiﬁcantly decreased, whereas arachidic acid (C20:0) was in-
creased (4-fold). In addition, baicalein-tri-Me showed a ten-
dency to decrease the C26:0 content at the concentration of 30
lM, though no substantial decrease was observed. Since behe-
nic acid (C22:0) content is assumed to be little inﬂuenced by
normal culture conditions, the ratio of C24:0/C22:0 or C26:0/
C22:0 was generally used as an index of the VLCFA accumu-
lation. However, C22:0 was signiﬁcantly decreased by the
Fig. 4. Fatty acid analysis of X-ALD ﬁbroblasts by gas–liquid chromatography. After the treatment of baicalein-tri-Me at a ﬁnal concentration of 0,
10 or 30 lM for two weeks, total fatty acids were extracted and analyzed by gas–liquid chromatography. The values of X-ALD (black bars) and
normal (gray bar) ﬁbroblasts are expressed as a % of total lipids. A statistical analysis was done according to Students t test. (\, P < 0.05 vs. ALD 0).
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of certain fatty acids as a percentage of the total fatty acids (as
in [24,25]).
3.5. Incorporation of VLCFA into cholesteryl esters in X-ALD
ﬁbroblasts
In X-ALD patients, VLCFA is reported to accumulate in
adrenal cortex, mostly as cholesteryl esters [26]. Cholesteryl es-
ters are also detected in the brains of X-ALD patients, whereas
virtually no VLCFA-cholesteryl esters are present in the brains
of normal subjects. The eﬀect of baicalein-tri-Me on the incor-
poration of lignoceric acid into cholesteryl ester was examined.
Fig. 5 shows that the incorporation of [1-14C]lignoceric acidControl  X-ALD
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Fig. 5. The eﬀect of baicalein-tri-Me on the incorporation of VLCFA
into cholesteryl esters in X-ALD ﬁbroblasts. Normal and X-ALD
ﬁbroblasts were cultivated for two weeks in the presence of 10 or 30
lM baicalein-tri-Me. [1-14C]Lignoceric acid was incorporated for 6 h
and the cellular lipids were extracted by the Bligh and Dyer method
[17]. Lipids were separated by TLC. Cholesteryl oleate, triolein,
cholesterol, oleate and phosphatidyl choline were co-developed by
standard methods. Radioactivities in the cholesterol ester fractions
were quantiﬁed with a BAS 5000. Figures are expressed as a % of the
total lipids.into the cholesteryl ester in X-ALD ﬁbroblasts was about 4
times higher than that in normal ﬁbroblasts. The incorporation
was markedly decreased in baicalein-tri-Me-treated X-ALD
ﬁbroblasts. At the concentration of 30 lM, the value was close
to that of normal ﬁbroblasts. The incorporation into triacyl-
glycerol was also decreased by the treatment but the radioac-
tivities in the phospholipid fraction were not signiﬁcantly
changed (data not shown).4. Discussion
The abnormal accumulation of VLCFA is thought to be
caused by the reduction of peroxisomal b-oxidation activity
[27] and/or the acceleration of microsomal elongation [28]. Re-
cently, Heinzer et al. [29] have suggested that the accumulation
in ALD knockout mouse is not due to a decrease of VLCFA b-
oxidation but rather the disruption of other VLCFA metabolic
pathways. Although both the mechanisms of VLCFA accumu-
lation and the role(s) of ALDP in VLCFA homeostasis are still
largely unknown, VLCFA accumulation is the hallmark of this
disease, and a reduction of the VLCFA accumulation in the
brain and adrenal gland of X-ALD patients could be a reason-
able target for therapy. It was found that several ﬂavonoids
stimulated VLCFA b-oxidation (Fig. 1). This ﬁnding
prompted an examination of whether these ﬂavonoids have
an ability to normalize the abnormal lipid metabolism of X-
ALD ﬁbroblasts. In this screening we used lovastatin as posi-
tive control, since Singh et al. [22] demonstrated that lovastatin
stimulated the VLCFA b-oxidation in X-ALD ﬁbroblasts in
standard cultured conditions. However, lovastatin may not
be suited as positive control, since recently McGuinness et
al. [30] noted that lovastatin could only increase VLCFA b-
oxidation in the cells when they were grown in cholesterol-free
media.
Baicalein-tri-Me tended to decrease the VLCFAs (C24:0 and
C26:0) level in X-ALD ﬁbroblasts (Fig. 4). Lovastatin and 4-
phenyl butyrate treatment are reported to lower the levels of
M. Morita et al. / FEBS Letters 579 (2005) 409–414 413VLCFA in X-ALD ﬁbroblasts concomitant with an increase of
ALDP-related protein (ALDRP/ABCD2) expression [22,25].
Monounsaturated fatty acids are also reported to reduce the
VLCFA level in X-ALD ﬁbroblasts due to the inhibition of
fatty acid elongation [28]. Although the mechanism by which
baicalein-tri-Me reduces the VLCFA level remains to be eluci-
dated, the stimulation of VLCFA b-oxidation could, if not
completely, be involved in the decrease of the VLCFA level.
It is unlikely that the stimulation of VCLFA b-oxidation was
caused by the induction of ALDRP, because the ALDRP
was not detected by immunoblotting in baicalein-tri-Me-trea-
ted X-ALD ﬁbroblasts (data not shown). McGuinness et al.
[23] have reported that the rate of peroxisomal VLCFA b-oxi-
dation is aﬀected by the rate of mitochondrial LCFA b-oxida-
tion. It might be that baicalein-tri-Me activated mitochondrial
b-oxidation, which in turn leads to the stimulation of peroxi-
somal VLCFA b-oxidation (Table 1).
The accumulation of esteriﬁed cholesterol with carbon
lengths of 22–30 in the adrenal glands of X-ALD patients re-
sults in a reduction of the conversion of cholesterol into active
hormonal steroids such as estrogen and testosterone. Recently,
Petroni et al. [31] have reported that testosterone metabolites
decreased the incorporation of VLCFA into the cholesteryl es-
ter fraction in X-ALD ﬁbroblasts. In the present study,
enhancement of the incorporation of [1-14C]lignoceric acid into
the cholesteryl ester fraction in X-ALD ﬁbroblasts was mark-
edly repressed by baicalein-tri-Me treatment (Fig. 5). Incorpo-
ration of [14C]cholesterol into the cholesterol ester fraction in
X-ALD ﬁbroblasts has been reported to be no diﬀerent from
that in normal ﬁbroblasts [32]. This result suggests that this ﬂa-
vonoid may have a therapeutic potential in the resumption of
healthy hormonal synthesis in X-ALD. The mechanism by
which baicalein-tri-Me interferes with the cholesteryl ester pro-
duction is under active investigation.
Baicalein is known to be metabolized to baicalin by conjuga-
tion with glucuronic acid at the 7-hydroxyl group, in order to
be eliminated from the body. In contrast, baicalein-tri-Me is
thought to be scantly metabolized because of the presence of
the methoxy residues. In addition, the methoxyl residues are
important for the activity of the compound (Fig. 3), suggesting
the possibility that structural analogs may possess a greater
potency. Recently, certain ﬂavonoids have been reported to
cross the blood–brain barrier and exhibit bioactive eﬀects
[33,34]. Since the reduction of accumulated VLCFA in the
brain seems to be crucial for preventing the progression of neu-
rological symptoms in X-ALD, any compounds able to cross
the blood–brain barrier and decrease the VLCFA levels would
be a highly attractive candidate for more eﬀective treatment in
ALD patients. Continued pharmacological studies of ﬂavo-
noids and chemically modiﬁed derivatives may lead to great
advances in the pharmacological therapy of X-ALD.
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